Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Q901 |
| Synonyms | |
| Therapy Description |
Q901 selectively inhibits CDK7, potentially resulting in cell cycle arrest and inhibition of tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 1953, Cancer Res 2020;80(16 Suppl):Abstract nr 4855). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Q901 | Q 901|Q-901 | CDK7 Inhibitor 16 | Q901 selectively inhibits CDK7, potentially resulting in cell cycle arrest and inhibition of tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 1953, Cancer Res 2020;80(16 Suppl):Abstract nr 4855). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05394103 | Phase Ib/II | Q901 | Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Recruiting | USA | 1 |